Frontotemporal Dementia PBMC

Frontotemporal Dementia PBMC

Frontotemporal Dementia PBMC is collected from IRB-consented donors diagnosed with clinically confirmed Frontotemporal Dementia (FTD). These peripheral blood mononuclear cell (PBMC) samples are ideal for profiling peripheral immune cells involved in neuroinflammation and neurodegeneration. PBMCs from FTD donors are valuable for studying immune dysregulation, transcriptomics, and neurodegenerative disease mechanisms.

Product Features

  • Cryopreserved, clinically verified FTD PBMC samples
  • Cryopreserved to ensure stability and long-term storage
  • Research Use Only (RUO)

De-identified Donor Data

  • Clinically confirmed FTD diagnosis
  • Donor demographics: age, sex assigned at birth, ethnicity
  • Medical and treatment history available when applicable

Applications

  • Profiling peripheral immune cells involved in neuroinflammation and neurodegeneration
  • Biomarker discovery and validation
  • Transcriptomic, proteomic, or functional studies
  • Custom assay development and disease modeling

Compliance and Quality

  • IRB-approved collection and electronic informed consent
  • HIPAA-compliant donor data handling

Ordering and Customization

Frontotemporal Dementia PBMC is available in standard and custom volumes. Contact learnmore@sanguinebio.com for international requests or documentation needs.

Protocols & Documentation

  • PBMC Isolation from Whole Blood

    Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.

    Download
  • Immune Cell Isolation

    Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.

    Download
  • Choosing the Right PBMC Configuration

    Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.

    Download
  • Thawing Cryopreserved PBMC

    Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

PBMC

Frequently Asked Questions

Showing 25–30 of 30 results

Do PBMCs come with flow cytometry data, clinical patient information, or treatment status details?

1 Answer

Electronic medical records are an option to be included with the PBMC sample, as well as, flow cytometry and other phenotypic testing.

YES – we can often accommodate treatment-naive samples including various cancers, and you can specify immunosupression status or other requirements in the I/E criteria.

Self-reported infectious disease testing is always available and some of our products have additional testing.

HLA-typing is available for some of our PBMC products.

YES to both – Unique donors can be specified, and multiple vials from the same donor can be arranged. You can specify these requirements when ordering.

Healthy PBMCs achieve over 90% vialbity post-thaw. Although our disease-state PBMCs are processed with same stringent SOP, there is more variability depending upon disease. Learn more about our post thaw viability here. https://sanguinebio.com/pbmc-viability-quality-assurance/

1 2 3
×

Ask a Question

Need a custom PBMC cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information